Latest Receptos Inc (RCPT) Headlines Why Recept
Post# of 69
Posted On: 03/13/2014 1:48:02 AM
Latest Receptos Inc (RCPT) Headlines
Why Receptos Inc. Shares Briefly Popped
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 3:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Receptos , a clinical-stage...
Receptos Reports Fourth Quarter and Year End 2013 Operational and Financial Results
GlobeNewswire - Wed Mar 05, 3:06PM CST
- Favorable interim results from Phase 2 trial of RPC1063 in relapsing multiple sclerosis consistent with differentiated profile; top-line data expected mid-2014 -
Receptos to Hold Fourth Quarter and Year End 2013 Financial Results Conference Call and Webcast
GlobeNewswire - Thu Feb 27, 8:52AM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the fourth quarter and year ended December 31, 2013 on Wednesday, March 5, 2013 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time).
Sheila Gujrathi, M.D., Joins Ambrx Board of Directors
PR Newswire - Mon Feb 24, 8:00AM CST
Ambrx Inc. today announced that Sheila Gujrathi, M.D., has joined its board of directors. Dr. Gujrathi is currently the chief medical officer at Receptos (Nasdaq: RCPT) where she is responsible for the clinical development of therapeutic candidates for the treatment of immune and metabolic diseases.
5 Biotech Stocks Spiking on Unusual Volume
at The Street - Mon Feb 10, 7:42AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Will Receptos (RCPT) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 6:25AM CST
Will Receptos (RCPT) Continue to Surge Higher?
Analyst Reason No. 345 to Upgrade Biotech Stocks: Takeover Rumors in the Foreign Press!
at The Street - Fri Jan 24, 2:40PM CST
In the past two months, BMO Capital Markets biotech analyst Jim Birchenough has upgrade stocks based on takeover rumors published in overseas newspapers.
Receptos Announces Closing of Underwritten Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Jan 14, 8:46AM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today closing of the previously announced underwritten public offering of 3,320,000 shares of its common stock at a price to the public of $30.75 per share, as well as the full exercise of the option granted to the underwriters to purchase an aggregate of 498,000 additional shares of common stock. The gross proceeds to Receptos from this offering were approximately $117.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering were sold by Receptos.
Stock Price Movements, FDA Applications, Appointments, and Clinical Study Updates - Research Report on Alere, ARCA, Achillion, Idenix Pharmaceuticals, and Receptos
PR Newswire - Mon Jan 13, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Alere Inc. (NYSE: ALR), ARCA biopharma, Inc. (NASDAQ: ABIO), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and Receptos, Inc. (NASDAQ: RCPT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Receptos (RCPT) in Focus: Stock Moves 12.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 10, 8:46AM CST
Receptos was a big mover last session, with shares rising nearly 13%.
Nasdaq stocks posting largest volume increases
AP - Thu Jan 09, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 09, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Receptos Inc prices public offering of common stock at USD30.75 per share
M2 - Thu Jan 09, 3:55AM CST
Biopharmaceutical company Receptos Inc (NasdaqGS:RCPT) said on Wednesday that it has priced a public offering of 3,320,000 shares of its common stock.
Receptos Announces Pricing of Underwritten Public Offering of Common Stock
GlobeNewswire - Wed Jan 08, 8:42PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today the pricing of an underwritten public offering of 3,320,000 shares of its common stock at a price to the public of $30.75 per share. The gross proceeds to Receptos from this offering are expected to be approximately $102.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering are to be sold by Receptos. In addition, Receptos has granted the underwriters a 30-day option to purchase up to an aggregate of 498,000 additional shares of common stock. The offering is expected to close on or about January 14, 2014, subject to customary closing conditions.
Receptos Inc proposes public offering of common shares
M2 - Tue Jan 07, 5:42AM CST
Biopharmaceutical company Receptos Inc (NasdaqGS:RCPT) said on Monday that it plans to offer shares of its common stock in an underwritten public offering.
Receptos Inc to initiate Phase 3 trial of RPC1063 in relapsing multiple sclerosis in Mid-2014 after announcing Phase 2 topline results
M2 - Tue Jan 07, 5:37AM CST
Biopharmaceutical company Receptos Inc (NasdaqGS:RCPT) revealed on Monday the completion of the enrolment of the first patients under the Phase 3 portion of RADIANCE Phase 2/3 study of RPC1063 in relapsing multiple sclerosis (RMS).
Receptos Begins Enrollment of Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
GlobeNewswire - Mon Jan 06, 3:05PM CST
- Pivotal Phase 3 Trial is Underway with First Patients Randomized in December 2013 -
Receptos Announces Proposed Underwritten Public Offering of Common Stock
GlobeNewswire - Mon Jan 06, 3:05PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today that it intends to offer shares of its common stock in an underwritten public offering. All shares of common stock to be sold in the offering will be offered by Receptos. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
A Closer Look at Multiple Sclerosis Treatments in 2014: BIIB, NVS, TEVA, SNY, RCPT
Leo Sun, The Motley Fool - Motley Fool - Thu Dec 26, 1:35PM CST
Follow @leokornsun // full story)
A Year-End Look at 3 High-Flying Biotech IPOs of 2013: PETX, RCPT, STML
Leo Sun, The Motley Fool - Motley Fool - Thu Dec 26, 9:41AM CST
Follow @leokornsun // full story)
Why Receptos Inc. Shares Briefly Popped
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 3:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Receptos , a clinical-stage...
Receptos Reports Fourth Quarter and Year End 2013 Operational and Financial Results
GlobeNewswire - Wed Mar 05, 3:06PM CST
- Favorable interim results from Phase 2 trial of RPC1063 in relapsing multiple sclerosis consistent with differentiated profile; top-line data expected mid-2014 -
Receptos to Hold Fourth Quarter and Year End 2013 Financial Results Conference Call and Webcast
GlobeNewswire - Thu Feb 27, 8:52AM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the fourth quarter and year ended December 31, 2013 on Wednesday, March 5, 2013 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time).
Sheila Gujrathi, M.D., Joins Ambrx Board of Directors
PR Newswire - Mon Feb 24, 8:00AM CST
Ambrx Inc. today announced that Sheila Gujrathi, M.D., has joined its board of directors. Dr. Gujrathi is currently the chief medical officer at Receptos (Nasdaq: RCPT) where she is responsible for the clinical development of therapeutic candidates for the treatment of immune and metabolic diseases.
5 Biotech Stocks Spiking on Unusual Volume
at The Street - Mon Feb 10, 7:42AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Will Receptos (RCPT) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 6:25AM CST
Will Receptos (RCPT) Continue to Surge Higher?
Analyst Reason No. 345 to Upgrade Biotech Stocks: Takeover Rumors in the Foreign Press!
at The Street - Fri Jan 24, 2:40PM CST
In the past two months, BMO Capital Markets biotech analyst Jim Birchenough has upgrade stocks based on takeover rumors published in overseas newspapers.
Receptos Announces Closing of Underwritten Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Jan 14, 8:46AM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today closing of the previously announced underwritten public offering of 3,320,000 shares of its common stock at a price to the public of $30.75 per share, as well as the full exercise of the option granted to the underwriters to purchase an aggregate of 498,000 additional shares of common stock. The gross proceeds to Receptos from this offering were approximately $117.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering were sold by Receptos.
Stock Price Movements, FDA Applications, Appointments, and Clinical Study Updates - Research Report on Alere, ARCA, Achillion, Idenix Pharmaceuticals, and Receptos
PR Newswire - Mon Jan 13, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Alere Inc. (NYSE: ALR), ARCA biopharma, Inc. (NASDAQ: ABIO), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and Receptos, Inc. (NASDAQ: RCPT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Receptos (RCPT) in Focus: Stock Moves 12.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 10, 8:46AM CST
Receptos was a big mover last session, with shares rising nearly 13%.
Nasdaq stocks posting largest volume increases
AP - Thu Jan 09, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 09, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Receptos Inc prices public offering of common stock at USD30.75 per share
M2 - Thu Jan 09, 3:55AM CST
Biopharmaceutical company Receptos Inc (NasdaqGS:RCPT) said on Wednesday that it has priced a public offering of 3,320,000 shares of its common stock.
Receptos Announces Pricing of Underwritten Public Offering of Common Stock
GlobeNewswire - Wed Jan 08, 8:42PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today the pricing of an underwritten public offering of 3,320,000 shares of its common stock at a price to the public of $30.75 per share. The gross proceeds to Receptos from this offering are expected to be approximately $102.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering are to be sold by Receptos. In addition, Receptos has granted the underwriters a 30-day option to purchase up to an aggregate of 498,000 additional shares of common stock. The offering is expected to close on or about January 14, 2014, subject to customary closing conditions.
Receptos Inc proposes public offering of common shares
M2 - Tue Jan 07, 5:42AM CST
Biopharmaceutical company Receptos Inc (NasdaqGS:RCPT) said on Monday that it plans to offer shares of its common stock in an underwritten public offering.
Receptos Inc to initiate Phase 3 trial of RPC1063 in relapsing multiple sclerosis in Mid-2014 after announcing Phase 2 topline results
M2 - Tue Jan 07, 5:37AM CST
Biopharmaceutical company Receptos Inc (NasdaqGS:RCPT) revealed on Monday the completion of the enrolment of the first patients under the Phase 3 portion of RADIANCE Phase 2/3 study of RPC1063 in relapsing multiple sclerosis (RMS).
Receptos Begins Enrollment of Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
GlobeNewswire - Mon Jan 06, 3:05PM CST
- Pivotal Phase 3 Trial is Underway with First Patients Randomized in December 2013 -
Receptos Announces Proposed Underwritten Public Offering of Common Stock
GlobeNewswire - Mon Jan 06, 3:05PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today that it intends to offer shares of its common stock in an underwritten public offering. All shares of common stock to be sold in the offering will be offered by Receptos. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
A Closer Look at Multiple Sclerosis Treatments in 2014: BIIB, NVS, TEVA, SNY, RCPT
Leo Sun, The Motley Fool - Motley Fool - Thu Dec 26, 1:35PM CST
Follow @leokornsun // full story)
A Year-End Look at 3 High-Flying Biotech IPOs of 2013: PETX, RCPT, STML
Leo Sun, The Motley Fool - Motley Fool - Thu Dec 26, 9:41AM CST
Follow @leokornsun // full story)
(0)
(0)Receptos Inc. (RCPT) Stock Research Links
Scroll down for more posts ▼